Sherry Glied and Richard Frank comment on CMS's coverage and savings estimates for the Medicaid work requirements rule.

Christen Linke Young, Richard Frank, and Rachel Sachs explore the potential role of international prices in the U.S. drug policy today.

Additional cuts in funding and staffing at the NIH and FDA could portend serious risks to the American public.

Richard Frank and Yihan Shi investigate the net sales of drugs selected for the second round of negotiation and future drug selections.

Rather than reinvent government to better serve the American people, as his predecessors sought to do, HHS Secretary Kennedy has made government less efficient and effective.

Proposed cuts to Medicaid could undo advances in treatment for opioid use disorders, risking more overdoses, deaths and stress on the U.S. health system

Richard G. Frank reviews the role of Medicaid in treating opioid use disorders and the impacts of policies intended to cut funding.

This Viewpoint focuses on the Manufacturer Discount Program, identifying 4 key themes of interest to policymakers that may be affected by its Part D redesign.

Richard G. Frank and Julia Paris present research on the projected changes in the U.S workforce and its impacts on occupational injury risks.

Richard G. Frank responds in an op-ed to claims regarding investments in drug research and development and drug pricing negotiations.